At a glance
- Humanin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 550 publications mentioning it, including 5 randomized controlled trials and 140 animal-only studies.
- ClinicalTrials.gov lists 3 registered studies testing it (1 active).
- FDA's adverse event system (FAERS) holds 1 report mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Humanin variants differentially regulate BID fibrilization and suppress BAX- and BID-dependent membrane permeabilization.
- Mitochondrial-derived peptides in female reproduction: Emerging regulators of oocyte competence and novel therapeutic opportunities for infertility.
- Humanin attenuates neuronal cellular senescence and preserves neurotransmitter release in differentiated PC12 cells.
- Humanin Attenuates Inflammatory Liver Injury and NF-κB Activation During Systemic Hypervirulent Klebsiella pneumoniae Infection.
- Mitochondrial Peptide SHLP2 Limits Poly(I: C)-Induced Alveolar Epithelial Injury by Modulating Redox, Apoptotic, Inflammatory, and Inflammasome Responses.
- The MTRNR2L gene family and age-related macular degeneration.
- [Effects of cardiac rehabilitation and predictive value of Humanin/CRP ratio in patients with acute exacerbation of chronic heart failure].
- Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications.
- Low Dose Ketamine Preconditions Astrocyte Mitochondria to Achieve Antidepressant Efficacy via Adenosine, Humanin, and Melatonin Upregulation and Efflux.
- S14G-humanin attenuates renal ischaemia-reperfusion injury, potentially through activation of STAT3 and ERK1/2 signalling pathways in rats.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 3
- Active
- 1
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation | Recruiting | N/A | March 1, 2026 |
| Clinical Value of Plasma Humanin in Acute Kidney Injury | Unknown status | — | August 1, 2022 |
| Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation | Completed | — | January 1, 2018 |
All 3 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.